This study was designed to determine the threshold of AR for immuohistochemical evaluation (minimum staining required for a tumor to be considered AR+), to analyze the clinicopathologic features of TNBCs expressing AR, and to determine the utility of AR immunoexpression as a prognostic and predictive marker in TNBC. Here, AR is linked to neoplasm.